Skip to main content
Selvita S.A. logo

Selvita S.A. — Investor Relations & Filings

Ticker · SLV ISIN · PLSLVCR00029 LEI · 25940057WQ9YP5MOQF28 WAR Professional, scientific and technical activities
Open in API
Filings indexed 1,179 across all filing types
Latest filing 2024-05-07 M&A Activity
Country PL Poland
Listing WAR SLV

About Selvita S.A.

https://selvita.com/

Selvita S.A. is a preclinical contract research organization (CRO) providing integrated services for the pharmaceutical and biotechnology sectors. The company offers comprehensive solutions across the drug discovery and development continuum, from target validation to preclinical candidate nomination. Core drug discovery capabilities include medicinal chemistry, pharmacology, DMPK, and protein sciences, supporting a wide range of modalities such as small molecules, antibodies, and protein degraders. For drug development, Selvita provides analytical support for small and large molecules, formulation, microbiology services, and manufacturing for clinical trials. The company operates under GMP and GLP quality standards, offering flexible engagement models that range from standalone studies to fully integrated programs.

Recent filings

Filing Released Lang Actions
Zawarcie umowy nabycia przez Selvita S.A. 100% udziałów w PozLab sp. z o.o. - zamknięcie Transakcji / Closing of an acquisition of PozLab sp. z o.o. by Selvita S.A. - Content (PL)
M&A Activity Classification · 99% confidence The document text describes a definitive agreement (Umowa) for the acquisition (nabycia) of 100% of the shares (Udziały) in PozLab sp. z o.o. by Selvita S.A. for a total price of 25,000,000 PLN. This transaction involves a merger or takeover activity (acquisition of another company). Based on the provided definitions, this clearly falls under 'M&A Activity' (Code: TAR). The document is a detailed report of the transaction, not just an announcement of a report's publication.
2024-05-07 Polish
Otrzymanie istotnego zlecenia / Receipt of a significant purchase order - Content (EN)
Regulatory Filings Classification · 90% confidence The document announces the receipt of a significant purchase order (Order) for integrated drug discovery (IDD) services, detailing the scope, duration (18 months), and value (EUR 3,348,577). This type of announcement, concerning a major business contract or transaction that is material to the company's operations and financial outlook, does not fit neatly into standard periodic reports (10-K, IR, ER) or specific corporate actions (DIV, SHA, DIRS). It is a material business update. Since there is no specific category for 'Major Contract Award' or 'Business Update,' and given the nature of the announcement (a specific, material event disclosure), the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for significant, non-standard regulatory disclosures, often seen in European markets for material information.
2024-04-12 English
Otrzymanie istotnego zlecenia / Receipt of a significant purchase order - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Management Board ("Zarząd") of Selvita S.A. regarding receiving a significant contract ("Zlecenie") from a client for drug discovery services. It details the scope, duration (18 months), and value (EUR 3.348 million) of the contract, concluding that the Management Board considers the order significant. This type of announcement, detailing a major business contract or transaction that is material to the company's operations or financial standing, fits best under the category of a general regulatory announcement or a significant business update. Since there is no specific category for 'Major Contract Award,' and it is not a standard financial report (10-K, IR, ER), nor a management change (MANG) or director dealing (DIRS), it falls under the general regulatory/miscellaneous category, RNS, as per the provided definitions, or potentially a Capital/Financing Update (CAP) if the contract was related to financing, which it is not. Given the nature of reporting a material business event, RNS is the most appropriate fallback.
2024-04-12 Polish
Powiadomienie
Director's Dealing Classification · 100% confidence The document text is a formal notification, written in Polish, detailing a transaction involving shares by a person discharging managerial responsibilities ('osób pełniących obowiązki zarządcze'). Key phrases include 'Powiadomienie o transakcji/transakcjach' (Notification of transaction/transactions) and references to 'art. 19 ust. 1 Rozporządzenia MAR' (Article 19(1) of the MAR Regulation). This structure explicitly identifies the document as a report of insider trading or director's dealing. Comparing this to the definitions, 'Director's Dealing (Code: DIRS)' is the most appropriate classification, as it covers 'Report of personal share transactions by company directors and executives (insider trades)'. The document is not a general regulatory filing (RNS) because it fits a specific category (DIRS).
2024-04-12 Polish
Powiadomienie od osoby pełniącej obowiązki zarządcze w Spółce - Art. 19 MAR / Notification from person discharging managerial responsibilities in the Company - Article 19 of MAR - Content (PL)
Director's Dealing Classification · 98% confidence The document text is very short (362 characters) and explicitly states that the content is a notification received regarding a transaction by a member of the Supervisory Board (Piotr Romanowski), which falls under MAR Regulation Article 19. This type of insider transaction disclosure is specifically categorized as Director's Dealing (DIRS). Although the text mentions the content is an attachment to the report, the primary subject matter is the director's dealing notification itself, which is a specific regulatory filing type, making DIRS more appropriate than the general RPA or RNS fallback, given the specific nature of the content described.
2024-04-12 Polish
Zawarcie warunkowej umowy nabycia przez Selvita S.A. 100% udziałów PozLab sp. z o.o. oraz ujawnienie opóźnionych informacji poufnych / The conditional agreement for the acquisition of 100% of the s...
M&A Activity Classification · 99% confidence The document text, written in Polish, details a conditional agreement for the acquisition of 100% of the shares in PozLab by Selvita S.A. This involves a purchase price, conditions precedent (including regulatory approval from NCBR), and the rationale for the transaction. The text explicitly mentions the delay in disclosing prior confidential information related to this negotiation process, citing Article 17 of EU Regulation No 596/2014 (MAR). This structure—announcing a significant transaction (acquisition/merger) and simultaneously disclosing previously delayed inside information—is characteristic of a major corporate event disclosure, often related to M&A activity. The closest matching category is 'M&A Activity' (TAR). While it is a formal report, the content is specifically about a takeover/acquisition proposal, not a general annual report (10-K) or an interim report (IR).
2024-03-28 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.